Avastin/Lucentis controversy continues

Article

"Why was Lucentis, at $2000 per dose chosen for the study, rather than Avastin at $50 per dose?? so asked Irv Arons in his blog spot.

“As I read the news release from the NEI/NIH yesterday morning, about the one-year results of the clinical trial evaluating the combination use of Lucentis with pan-retinal laser therapy to treat diabetic macular oedema, prior to posting it online, and later, when I read the complete study as posted in Ophthalmology, the one thought that kept running through my mind was, why was Lucentis, at $2000 per dose chosen for the study, rather than Avastin at $50 per dose?” so said Irv Arons in his blog spot. Read more...

What do you think? Tell us at www.oteurope.com/discuss

Related Videos
Josefina Botta, MD, MSc, at ASCRS 2024
Dr Nir Shoham Hazon, Director, Miramichi EyeNB Centre of Excellence, New Brunswick, Canada
J. Morgan Micheletti, MD, speaks at the 2024 ASCRS meeting
Dr William Wiley of Cleveland Eye Clinic, Northeast Ohio
Related Content
Hemoglobin molecule structure, rendered in pink and purple. Generative AI. Image credit: ©Electro Unicorn – stock.adobe.com

TEASE-3 study: Positive interim data are reported for Stargardt drug

April 25th 2024
Article

Gildeuretinol halts Stargardt disease progression, study results indicate

A researcher sits at a computer. Image credit: ©lightpoet – stock.adobe.com

Interactive vision simulator illustrates the vision loss caused by retinal diseases

April 23rd 2024
Article

The online tool shows vision loss simulations for diabetic macular oedema, diabetic retinopathy, age-related macular degeneration and other retinal diseases

Professor Ramin Tadayoni, MD, PhD. Image courtesy of EURETINA

Retina community mourns sudden loss of Ramin Tadayoni, MD, PhD

April 22nd 2024
Article

Prof Tadayoni was a much-admired leader, researcher, surgeon and EURETINA President

A cell in amniotic fluid. Image credit: ©Icruci – stock.adobe.com

Amniotic membrane could move the needle outside of the operating room

April 19th 2024
Article

The tissue serves as a testing ground for outpatient ocular therapies

Concept image for an exhibition hall crowded with people. Image credit: ©arhendrix – stock.adobe.com

Clinicians and researchers don’t shy away from hot topics in the field

April 18th 2024
Article

The 15th annual Congress on Controversies in Ophthalmology heads to Athens, Greece

An elderly woman undergoes an eye exam. Image credit: ©cherryandbees – stock.adobe.com

I-SCREEN programme will use AI and OCT imaging to identify and monitor AMD

April 17th 2024
Article

I-SCREEN will bring together 12 institutions across Europe, including Queen’s University Belfast

© 2024 MJH Life Sciences

All rights reserved.